Cyclosporin A instead of Tacrolimus for treatment of hemolytic uremic syndrome in a kidney transplant recipient
10.3969/j.issn.1673-8225.2010.05.034
- VernacularTitle:他克莫司替换环孢素A治疗溶血性尿毒综合征1例
- Author:
Jinguo WANG
;
Na WANG
;
Honglan ZHOU
;
Weigang WANG
;
Bo CHEN
;
Yaowen FU
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2010;14(5):903-905
- CountryChina
- Language:Chinese
-
Abstract:
A patient with impaired kidney function after kidney transplantation and received treatment at the First Hospital of Jilin University was retrospective analyzed. The patient was male, 45 years old, and was diagnosed hemolytic uremic syndrome by transplanted kidney biopsy. The patient received cyclosporine A (CsA) as maintenance centered immunosuppression therapy postoperatively. He was admitted because of 1 week acratia followed by 1 day increased serum creatinine level at 1.5 years after transplantation. At 1 day after admission, he was received renal needle biopsy, and underwent 2 days Prednlsolone treatment. After hemolytic-uremic syndrome was diagnosed, CsA was transferred to Tacrolimus (Fk506) with dose of 2 mg/d, and Azathioprine was replaced by mycophenolate, Prednisone was taken orally for 20 mg/d. The function of the transplanted kidney and the change of routine blood tests were observed. After 1 week treatment of the changed Immunosuppression therapy, the function of the transplanted kidney was improved obviously, and the hemoglobin and platelets was decreased during the treatment. The results demonstrated that kidney biopsy is a key method to diagnose hemolytic-uremic syndrome, and adjustment of immunosuppressive agents, replacing CsA with FK506 are effective for postoperative hemolytic-uremic syndrome.
